





Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)

Maurizio Fava¹ · Marlene P. Freeman¹ · Martina Flynn¹ · Heidi Judge¹ · Bettina B. Hoepfner¹ · Cristina Cusin¹ · Dawn F. Ionescu¹ · Sanjay J. Mathew² · Lee C. Chang² · Dan V. Iosifescu ³ · James Murrough³ · Charles DeBattista⁴ · Alan F. Schatzberg⁴ · Madhukar H. Trivedi ⁵ · Manish K. Jha⁵ · Gerard Sanacora⁶ · Samuel T. Wilkinson⁶ · George I. Papakostas¹

Published online: 7 January 2019
© Springer Nature Limited 2019

Correction to: Molecular Psychiatry

<https://doi.org/10.1038/s41380-018-0256-5>

Supplementary Figure 1 and Supplementary Tables 1–4 have been re-uploaded so as to reflect the versions supplied

during proofs stage. The publisher apologizes for the error in versioning. The HTML version of the paper has been updated.

Supplementary information The online version of this article (<https://doi.org/10.1038/s41380-018-0311-2>) contains supplementary material, which is available to authorized users.

✉ Maurizio Fava
mfava@mgh.harvard.edu

- ¹ Massachusetts General Hospital, Boston, MA, USA
- ² Baylor College of Medicine/Michael E. DeBakey VA Medical Center, Houston, TX, USA
- ³ Icahn School of Medicine at Mount Sinai, New York, NY, USA
- ⁴ Stanford University School of Medicine, Stanford, CA, USA
- ⁵ University of Texas Southwestern, Dallas, TX, USA
- ⁶ Yale University, New Haven, CT, USA